S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

High-Yield Dividend King Kimberly-Clark Is On Sale 

Tuesday, October 26, 2021 | Thomas Hughes
High-Yield Dividend King Kimberly-Clark Is On Sale 

Kimberly-Clark Says Toilet Paper Is Getting More Expensive 

Kimberly-Clark (NYSE: KMB) didn’t have a good or a bad quarter, just one that highlights issues that are building within the market. The number one is inflation. The company blames inflationary pressures it was slow to combat for weak earnings and has vowed to fight against the evil of margin shrinkage with higher prices. What this means, and will mean in future quarters, is that a fair portion of revenue and earnings growth is due to higher prices and not organic growth. At some point, the scales will tip and higher prices will curb sales but we aren’t there yet. 

“... Our earnings were negatively impacted by significant inflation and supply chain disruptions that increased our costs beyond what we anticipated.  We are taking further action, including additional pricing and enhanced cost management, to mitigate these headwinds as it is becoming clear they are not likely to be resolved quickly," said CEO Mike Hsu.  

The good news for Kimberly-Clark is that its tissue paper products are among the most must-have of all the consumer staples making it a safer-than-average play for these uncertain times. If we add in the facts the stock trades at a discount to the broad market, yields nearly 3.5%, and has been increasing the dividend for 50 years and you may understand why we view today’s sell-off as an attractive time to buy

Nothing To Brag About In Kimberly-Clark’s Numbers 

Kimberly-Clark had a quarter despite the mounting headwinds plaguing the market but that is about the best we can say about it. The $5.01 billion in net revenue is up 7.1% from last year but there are so many factors impacting the growth that are not related to volume the numbers don’t mean what it should. 

On an organic basis, the company grew about 4% to beat the Marketbeat.com consensus but that is due to a 3% increase in selling prices and a 1% tailwind from mix, not volume. As for the rest of the 7.1% in growth, the company posted 200 basis points of growth from acquisition and another 100 from FX tailwinds. Nice to see but, once again, not really much to brag about. On a segment basis, a 14% increase in Personal Care products and 13% increase in K-C Professional was offset by a 5% decline in Consumer Tissue. 

Moving down to the margins, there is even less to get excited about. The company reported a contraction in the operating margin that more than offset the revenue gains and leave profits down slightly on a YOY basis. This put GAAP earnings at $1.39 or a penny more than last year but $0.16 short of the consensus and adjusted earnings at $1.62 or a dime less than last year and $0.03 less than expected. 

Kimberly-Clark Is Safely Growing The Dividend 

Kimberly-Clark is safely growing its dividend and paying a high 3.45% yield but we think the days of aggressive increases are over. The revenue and earnings are enough to cover the payout and sustain growth but, at 70%, the payout ratio is sufficiently high to preclude a large increase especially with margin pressure the concern that it is. We don’t expect dividend hikes to cease, just to slow. If the company can overcome the rot of inflation and widen margins a larger increase could come back on the table. 

The Technical Outlook: Kimberly-Clark, They’re Buying The Dip

Shares of Kimberly-Clark shed more than 7% in the wake of the Q3 earnings report but appear to have stumbled into a buying opportunity. Price action is confirming support at the $128 level and may continue higher in the near term. The next target for resistance is at the top of the price gap near $131 and may be strong. If price action can get above that level a move higher is possible but resistance will remain at the 30-day moving average. The best-case scenario, in our opinion, is that price action will trend sideways near these levels until a clearer picture of the future can be visualized. 

High-Yield Dividend King Kimberly-Clark Is On Sale 

Should you invest $1,000 in Kimberly-Clark right now?

Before you consider Kimberly-Clark, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kimberly-Clark wasn't on the list.

While Kimberly-Clark currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Kimberly-Clark (KMB)2.7$135.27+0.0%3.37%23.01Hold$134.00
Compare These Stocks  Add These Stocks to My Watchlist 


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.